Veracyte, Inc.

We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.

[Veracyte, Inc. @Veracyte]

Today, we announced third-quarter 2026 financial results, reflecting continued momentum across our #CancerDiagnostics portfolio:

🔹 $151.8 million in total revenue, up 15% year over year

🔹 $146.4 million in testing revenue, up 15% year over year

🔹 $41.2 million in adjusted EBITDA, representing 27.2% of revenue

| Q3 Highlights |

🔹 Acquired Convergent Genomics, Inc., expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey.

🔹 Secured Medicare reimbursement for the Prosigna® Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients* with early-stage HR+ breast cancer.

🔹 Surpassed more than 1 million patients served with our high-performing molecular tests.

| Resources |

🔹 View #Q3Earnings Presentation - https://t.co/pxrZB3360v

🔹 Explore our technology and pipeline - https://t.co/szRqJ0ukwF

🔹 Learn about some of our active clinical studies - https://t.co/0Ha1fJFau2

#Veracyte #InvestorRelations $VCYT #PrecisionMedicine

| Notes |

* Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.

** This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://t.co/tltSRBtiSL

[Veracyte, Inc. @Veracyte]

10 abstracts involving our Afirma® Genomic Sequencing Classifier test and the Veracyte Genomic Resource for Intelligent Discovery (GRID), a research-use-only database, will be presented at the 2026 Annual Meeting of the American Thyroid Association (#ATA2026) in Philadelphia from November 4–7, 2026.

The presentations explore how gene expression can provide insights beyond individual genetic alterations to inform #ThyroidNodule diagnosis and assessment of cancer aggressiveness. Together, the studies build on Afirma’s long-established role in thyroid nodule diagnosis and explore how gene expression data can help researchers answer additional questions about cancer risk and biology.

Visit Booth #6 to connect with our team and learn more about the #AfirmaThyroid test.

| Key Presentation Highlights |

🔹 Oral presentations from Johns Hopkins and MD Anderson will examine potential imaging and treatment targets.

🔹 Posters include studies using the Veracyte GRID research-use-only database to investigate preoperative diagnosis and recurrence risk.

🔹 Additional posters will discuss independent research on molecular testing and long-term outcomes.

| Resources |

🔗 Read the full press release - https://t.co/g3nrhO7ySa

🔗 Event information -  https://t.co/ohM4xWlxVD

🔗 Afirma GSC - https://t.co/aq1RRYZqbS

#RealWorldEvidence #ThyroidHealth #ThyroidCare #AfirmaThyroid #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit -
https://t.co/fQcKkGFugi

[Veracyte, Inc. @Veracyte]

#ESMO26 is a wrap! Here are a few key moments (and some thank-yous) from the Veracyte team.

🔹 #STAMPEDE: Huge thank you to Dr. Sarah Howlett, M. B.B. S. of University College London (@ucl) for presenting results from a combination analysis of STAMPEDE and real-world datasets. Dr. Howlett shared that her findings show that the Decipher® Prostate test can predict benefit from adding abiraterone to androgen deprivation therapy in men with node-negative clinically very high-risk hashtag#ProstateCancer.

🔹 #OPTIMA: We are also grateful to Peter Hall, https://t.co/5qs3K7k1NT.B., M.R.C.P., Ph.D. from the University of Edinburgh for providing an economic analysis of the OPTIMA trial to explore the impact of chemotherapy decisions for HR+ early breast cancer patients, informed by the Prosigna® Breast ROR test. In the talk, Dr. Hall discussed how Prosigna test-directed chemotherapy lowered care costs and increased quality-adjusted life-years (QALYs) for patients. Combined with previous OPTIMA results showing that Prosigna test-directed treatment was non-inferior for 5-year invasive breast cancer-free survival, these data support wider adoption of the Prosigna Breast test in #BreastCancer care.*

🔹 IINTerpath-001: Georgina V. Long, PhD, MBBS, FRACP shared the first results from the Phase 3 INTerpath-001 trial, which showed that adding  intismeran autogene, an investigational mRNA vaccine tailored to the mutations in each patient’s tumor, to pembrolizumab reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone after surgery. While this isn’t Veracyte news, it’s a monumental moment for the #PrecisionOncology community and the first positive Phase 3 result for an mRNA cancer vaccines as a burgeoning modality. Although still early, seeing molecular insights from a patient’s own tumor shape treatment and improve outcomes is worth celebrating!

🔹 We'd also like to thank Alice Bernard-Tessier, M.D., Michela Piacentini, M.D., Melvin L.K. Chua, M.B.B.S., F.R.C.R., Ph.D., and Chiara Mercinelli, M.D. for presenting additional Decipher Urologic data, and all investigators, site teams, and participants who made this research possible.

🔗 To see where #TeamVeracyte is headed next, visit our upcoming events page - https://t.co/cfQrzWmGJk

#MedicalOncology #RWD #DecipherUrologicCancers #Prosigna

| Notes |

*Prosigna testing is available in the US as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York. The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as an IVD test in territories where registered.

**This article contains forward-looking statements, which involve risks and uncertainties.

[Veracyte, Inc. @Veracyte]

Join us at the 2026 American Thyroid Association Annual Meeting (#ATA2026) in Philadelphia from November 4th to November 7th!

Visit Booth #6 to connect with our team and learn how the market-leading* Afirma® Genomic Sequencing Classifier test combines transcriptome-wide analysis with real-world clinical evidence to help advance thyroid nodule care.

During the meeting, be sure to:

✅ Visit our professional headshot booth, open during exhibit hall hours
✅ Attend our sponsored product theater (see details below)
✅ Meet with our team to discuss the latest evidence supporting Afirma
✅ Explore the latest Afirma data by attending featured oral and poster presentations

| Product Theater Details |

📌 Title: The Afirma® GRID™ Research Tool Helps Drive Discovery for Future Patients
🎤 Presenters: Dr. Gustavo Romero-Velez (Cleveland Clinic), Dr. Arti Bhan (Henry Ford Health), Adeeb Ansari, MD (Director Medical Science Liaison, Veracyte)
📅 Date / Time: Thursday, November 5th at 10:25 AM–11:25 AM (EDT)
📍 Location: Expo Theater (Exhibit Hall)

| Key Oral Presentations |

📌 Title: mRNA Analysis of Cell-Surface Protein Targets in Medullary Thyroid Cancer Fine Needle Aspiration Samples
🎤 Presenter: Sarah Hamidi, M.D. (MD Anderson Cancer Center)
📅 Date/time: Thursday, November 5th, 5:30 PM - 5:45 PM (EDT)
📍 Location: Floor 5, Salon H

📌 Title: Prostate-Specific Membrane Antigen (PSMA) mRNA Expression in Thyroid FNA Samples with Bethesda III-VI Cytology Predicts Lymphatic and Angioinvasion in Surgically Resected Tumors
🎤 Presenter: Wassim Najjar, M.D. (John Hopkins University) and Prasanna Santhanam, MD (Johns Hopkins University)
📅 Date/time: Friday, November 6h, 5:30 PM - 5:45 PM (EDT)
📍 Location: Floor 5, Salon H

| Resources |

🔗 Event information: https://t.co/ohM4xWlxVD

📄 Download the Afirma 2025 Research Collection: https://t.co/O8RSzn5oOs

*Based on claims for CPT codes 81546, 0026U, 0245U as of 8/12/2026 – found at: https://t.co/7wz1xO3bqQ

#RealWorldEvidence #ThyroidNodules #ThyroidHealth #ThyroidCare #AfirmaThyroid #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. https://t.co/tltSRBtiSL

[Veracyte, Inc. @Veracyte]

We will report financial results for the third quarter of 2026 on November 4, 2026 at 4:30 PM ET. Join our conference call and webcast to learn more about the financial results and receive a general business update.

| Resources |

🔗 Access the live audio webcast here - https://t.co/70MrI0nelI

📄 Read the full announcement - https://t.co/6DjxaqqPFc

#Q3Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics $VCYT #CancerDiagnostics #PrecisionMedicine

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://t.co/tltSRBsL3d

[Veracyte, Inc. @Veracyte]

📰 New coverage in @thetimes of the landmark #OPTIMA trial features data presented at ESMO by Professor Peter Hall, health economist at the University of Edinburgh, showing potential healthcare system cost savings in the UK.

The OPTIMA trial demonstrated how the Prosigna® Breast Risk of Recurrence (ROR) test can help clinicians predict which patients may safely avoid chemotherapy.

🔗 Read the full article in The Times by Shaun Lintern -https://t.co/bYFlFt9Uf1

| About the #ProsignaTest |

🔗 Clinical resources: https://t.co/vGSwkG5t9B

🔗 How to order: https://t.co/xTz4mIDOm5

#ProsignaBreastRORTest #BreastCancer #PrecisionMedicine #CancerDiagnostics #TeamVeracyte @uclnews

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://t.co/fQcKkGEWqK

[Veracyte, Inc. @Veracyte]

New findings from the randomized Phase III STAMPEDE trial took the stage at #ESMO26 today. Here’s a recap from a session where Sarah Howlett, M.B.B.S., University College London (@ucl), presented results from a combination analysis of STAMPEDE and real-world datasets.

The talk highlighted how the Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk #ProstateCancer, whose disease had not spread to lymph nodes.

| Primary Takeaways |

🔹 Transcriptomic signatures showed consistent associations with metastatic outcomes across both STAMPEDE and real-world datasets.

🔹 Higher Decipher scores identified patients with higher rates of distant metastasis and those most likely to benefit from the addition of abiraterone.

🔹 Lower Decipher scores correlated with lower rates of distant metastasis, potentially providing means for guiding safe treatment de-escalation.

| Some Thank You’s |

💙 We’re grateful to Dr. Howlett for sharing this research with the oncology community and for her continued dedication to improving care for the millions of men living with prostate cancer worldwide.

💙 Thank you to everyone who joined the session and to the investigators, site teams, and participants whose contributions made this research possible.

| Additional Resources |

🔗 Event information - https://t.co/XNyfF7AfZ6

🔗 Decipher Prostate Genomic Classifier - https://t.co/6VCW4swBxK

#PrecisionOncology #ClinicalResearch #RealWorldData #DecipherProstate #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - https://t.co/fQcKkGEWqK

[Veracyte, Inc. @Veracyte]

We are proud to announce new Phase III study findings showing that the Decipher® Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk #ProstateCancer.

This retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher Prostate test in patients with clinically high-risk nonmetastatic prostate cancer whose disease had not spread to lymph nodes.

| Key Findings |

🔹 Decipher predicted benefit from adding abiraterone: The treatment-by-Decipher interaction for distant metastasis was statistically significant among node-negative patients (p=0.01), indicating that treatment benefit differed according to the Decipher score.

🔹 Patients with higher Decipher scores saw greater benefit: At five years, the benefit for adding abiraterone in terms of reducing distant metastasis events was 10% for patients with high scores and 11% for those with very high scores, compared to 2% benefit for those with lower scores.

🔹 Decipher scores helped identify differences in the risk of cancer spread: Higher scores were associated with greater distant-metastasis risk and worse metastasis-free and overall survival in the STAMPEDE cohort.

These findings build on Decipher’s established ability to help assess the risk of cancer progression, expanding the test’s predictive evidence to another consequential treatment decision.

Dr. Sarah Howlett, M. B.B. S. of University College London will present the completed results in a proffered paper oral presentation at the #ESMO26 Congress (Abstract 2045O).

| Presentation Details |

📌 Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically high-risk prostate cancer
📅 Date: Saturday, October 24
⏰ Time: 10:15 a.m. – 11:45 a.m. CEST
📍 Location: Barcelona Auditorium – Hall 9

| Resources|

📄  Read full press release - https://t.co/5vtmmXOOVs

🔗 Event information - https://t.co/XNyfF7AfZ6

#PrecisionOncology #ClinicalResearch #DecipherProstate #TeamVeracyte

This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: https://t.co/fQcKkGEWqK

[Veracyte, Inc. @Veracyte]

We are proud to share that we’ve secured Medicare reimbursement for the Prosigna® Breast Risk of Recurrence (ROR) test!

Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test for eligible patients with early-stage breast cancer, creating a reimbursement path for those patients and their physicians to receive critical genomic information to help guide their treatment.

The Prosigna Breast ROR test received coverage and reimbursement for its Technical Assessment submission through Palmetto GBA’s MolDX program.

Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) breast cancer who meet the applicable Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes.*

| Resources |

🔗 Read the full announcement - https://t.co/2yew0UCYwz

📄 Prosigna Breast ROR test - https://t.co/vGSwkG60Z9

#Medicare #BreastCancer #PrecisionOncology #ProsignaBreastTest #TeamVeracyte

| Notes |

* Centers for Medicare & Medicaid Services. MolDX Breast Cancer Assay Prosigna. Local Coverage Determination L36125. https://t.co/00QpWujDHs

** This article contains forward-looking statements, which involve risks and uncertainties. For more information, please visit https://t.co/fQcKkGFugi

*** Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.

[Veracyte, Inc. @Veracyte]

We’re proud to celebrate an important milestone: serving one million patients with our molecular tests.

We’ve reached this point by fulfilling our core promise: to empower clinicians with the high-value genomic insights they need to make more confident treatment decisions for their patients.

For us, every test is a promise kept.

Learn more about our mission to transform #CancerCare for patients all over the world - https://t.co/cZ2J5ZkO5L

#PrecisionOncology #MolecularTesting #CancerDiagnostics #TeamVeracyte

[Veracyte, Inc. @Veracyte]

Six studies involving our genomic tests across urologic and breast cancers will be presented at the European Society for Medical Oncology Congress 2026 (#ESMO26) in Madrid, Spain, from October 23rd to October 27th.

Together, the studies presented at ESMO will reflect how understanding a tumor’s biology can inform decisions across cancer care, addressing key questions for clinicians and patients alike.

| Key Oral Presentation Highlights |

🔹 The first evidence that the Decipher® Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy for patients with clinically very high-risk, nonmetastatic #ProstateCancer

🔹  A late-breaking health economic analysis of Prosigna®-guided chemotherapy decisions for high-risk early #BreastCancer from the Phase III landmark OPTIMA trial

| Resources |

🔗 Read the full press release - https://t.co/ufhgxHsolx

🔗 Event information - https://t.co/XNyfF7ANOE

🔗 Explore our portfolio of market-leading tests - https://t.co/szRqJ0ukwF

#PrecisionOncology #MedicalOncology #BladderCancer #DecipherUrologicCancers #ProsignaBreastTest #TeamVeracyte

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit -
https://t.co/fQcKkGFugi

[Veracyte, Inc. @Veracyte]

The Veracyte team is in Los Angeles for the American Academy of Otolaryngology–Head and Neck Surgery Annual Meeting and OTO Expo (#OTOMTG26), joining #ENT leaders from October 17th through the 20th to discuss molecular testing for #ThyroidCancer.

Stop by #Booth 1001 to talk with our team and learn how the Afirma® Genomic Sequencing Classifier (GSC) uses transcriptome-wide analysis of over 21,000 genes from patient fine-needle aspiration (FNA) samples to help conclusively rule out surgery and confidently guide treatment for #ThyroidNodules.

You can also ask our medical team about the latest updates to Afirma® GRID (Genomic Resource for Intelligent Discovery), a proprietary research-use-only* data resource, designed to help advance the understanding of thyroid nodules and thyroid cancer at the molecular level.

We look forward to seeing you there!

| Resources |

📅 Event information: https://t.co/3Un4SDx64P

🔗 Explore Afirma GSC: https://t.co/aq1RRYZqbS

🧬 Learn more about Afirma GRID: https://t.co/a3UXcdFScp

#Otolaryngology #HeadAndNeckSurgery #AfirmaThyroid #TeamVeracyte

| Notes |

*Afirma GRID data is for research use only and is not intended to guide patient management.

** This article contains forward-looking statements, which involve risks and uncertainties. For more information, please visit https://t.co/fQcKkGFugi

[Veracyte, Inc. @Veracyte]

At 47, Bora was balancing an office-based role as a local elected politician when she received a breast cancer diagnosis that came as a complete shock.

She had experienced lumpy breasts for 10 to 15 years, with changes that often became more noticeable during her menstrual cycle. When one lump did not go away, she arranged to have it checked. An ultrasound and biopsy confirmed breast cancer.

“I cried,” she says. “It was a total shock.”

Bora approached the diagnosis in a practical way, drawing on her previous experience as a journalist to research the disease and understand the available information. But the process was still difficult.

Referrals, appointments and decisions about surgery meant that roughly two weeks could pass between each step. She was referred to two surgeons while considering how to move forward with treatment as quickly as possible.

She chose to be open about her diagnosis and found that talking with friends and loved ones was an important source of support. Living alone, she particularly valued having people around her who could help her process what was happening.

After her second surgery, her care team needed to determine whether she required additional chemotherapy. The team told her about the OPTIMA trial, which, according to her team, was investigating whether genomic testing could help guide treatment decisions.

Bora had a positive view of clinical research and had already taken part in other studies. She discussed the trial information with friends who were oncologists and decided to participate.

Her main concern was whether she might get her hopes up, as she expected that chemotherapy would probably be recommended.

“To be honest, I kind of forgot I was involved in it,” she says. Participation involved completing a questionnaire about every three months, focused on lifestyle and how she was feeling.

For Bora, the experience reinforced the value of clear, personalized information.

“Data and information can be empowering when they are explained properly,” she says. “There are different types of breast cancer, treatment options and decisions. When testing is available alongside appropriate medical advice, it can help patients feel more empowered.”

🩷 In honor of #BreastCancerAwarenessMonth, join us in thanking the people, like Bora, who took part in the OPTIMA trial - https://t.co/x4O6U2SyuO

#BreastCancer #CancerClinicalTrials #BreastCancerResearch #BecauseTheySaidYes #ResearchIsTheReason #BreastCancerJourney

[Veracyte, Inc. @Veracyte]

Meet the inaugural winner of the Conquer Cancer®-Veracyte Endowed Young Investigator Award in Breast Cancer Genomics: Dr. Alexandra (Bili) Newman!

Dr. Newman is currently finishing her second year of a three-year fellowship in Hematology-Oncology at MD Anderson Cancer Center in Houston, with a clinical and research focus on #BreastCancer.

Her YIA project focuses on the role of post-transcriptional PTEN loss as a predictive biomarker of response to PI3K-targeted agents in advanced hormone-receptor positive breast cancer.

Recently, Veracyte sat down with Dr. Newman to discuss:

🔹 Her background

🔹 The YIA project and its professional significance

🔹 Why this research is important for patients

🔗 To learn more about Dr. Newman and her work, check out the full interview -  https://t.co/OsGVH0BalN

#BreastCancerAwarenessMonth #BreastCancerResearch #CancerGenomics #PrecisionOncology #ConquerCancer #TeamVeracyte

[Veracyte, Inc. @Veracyte]

Last week, Veracyte team members alongside Christy, a person diagnosed with breast cancer, and her family showed up on the TODAY show plaza in New York City to help kick off #BreastCancerAwarenessMonth!

The team arrived, signs in tow, to join the TODAY crowd at Rockefeller Center to help amplify the importance of #BreastCancerResearch and the people who make it possible.  Breast cancer research depends on brave people who say yes to clinical trials. Their courage drives new possibilities leading to better tests and treatments for the people who come next.

Christy’s treatment journey reflects the profound impact that clinical trial participants can have on other patients. Christy, a 51-year-old premenopausal mother, was able to avoid chemotherapy after receiving a low Risk of Recurrence score on the Prosigna® Breast Cancer test and consulting with her oncologist. That treatment decision was supported by clinical evidence made possible by participants in the landmark OPTIMA trial.

🩷 HUGE thank you to Christy, her family, and everyone else who showed up to help shine a spotlight on #BreastCancer!

📺 Check out the TODAY Plaza Cam clip here! https://t.co/15IAfwW4Dz

| #BecauseTheySaidYes |

🩷 If you'd like an opportunity to express your gratitude with breast cancer patients in clinical trials, join us in thanking the people who took part in the #OPTIMA trial - https://t.co/QZReHENjFW

#CancerClinicalTrials #ResearchIsTheReason

[Veracyte, Inc. @Veracyte]

Kathryn lives in the UK with her husband, Rick. The couple have been married for 28 years and have two grown-up daughters. At 50, Kathryn was diagnosed with breast cancer after attending her first routine NHS mammogram.

She underwent a mastectomy and had some lymph nodes removed before being referred to a specialist cancer center to discuss her next steps.

According to Kathryn, during her meeting with her doctors, she learned about the #OPTIMA trial and the possibility that she might not need chemotherapy.

“I was really surprised, as I’d just assumed I’d have to have chemo,” she says. “When I found out that I didn’t, I was over the moon.”

Instead of chemotherapy, Kathryn received other recommended treatments, including a targeted cancer drug, which she took for two years. Avoiding chemotherapy meant she was able to continue working as a teacher and maintain a routine close to her life before her diagnosis.

“I was able to keep doing the job I loved—teaching—and just got on with a life that was pretty close to how it was pre-diagnosis,” she says.

Following this experience, Kathryn says she has discovered a renewed enthusiasm for life. One of her daughters, a personal trainer and strength coach, encouraged her to start going to the gym. She also enjoys spending time in London visiting her other daughter.

“It’s given me a new zest for life,” Kathryn says. “Life is good.”

Kathryn says she had complete confidence in her clinical team and the trial and never had reservations about taking part.

“I know that without patients taking part in research, there won’t be any advances in treatment,” she says. “I was really happy to take part and would encourage other patients to say ‘yes’ too.”

🩷 In honor of #BreastCancerAwarenessMonth, join us in thanking the people, like Kathryn, who took part in the OPTIMA trial - https://t.co/QZReHENjFW

#BreastCancer #CancerClinicalTrials #BreastCancerResearch #BecauseTheySaidYes #ResearchIsTheReason #BreastCancerJourney

[Veracyte, Inc. @Veracyte]

#TeamVeracyte is here in Las Vegas October 3–6 for #CAP26! Stop by Booth 150 to learn how our tests assess the unique biology of each patient's tumor or nodule to help clinicians answer key questions and make confident decisions for thyroid, prostate, breast, and bladder cancer care.

Be sure to ask about:

🔹 Afirma® Genomic Sequencing Classifier:  helps clinicians conclusively rule out surgery and confidently guide treatment for thyroid nodules

🔹 Decipher® Bladder Genomic Classifier: provides deep biological insight into a patient’s bladder cancer to help guide personalized treatment decisions

🔹 Decipher® Prostate Genomic Classifier:  measures the expression of 22 genes in prostate cancer tissue to convey tumor aggressiveness and disease progression risk

🔹 Prosigna® Breast Risk of Recurrence Test: delivers comprehensive genomic insights to help make more informed breast cancer treatment decisions.

| Resources |

🔗 Afirma® Genomic Sequencing Classifier - https://t.co/aq1RRYZqbS

🔗 Decipher® Bladder Genomic Classifier - https://t.co/qGwpNYKVMv

🔗 Decipher Prostate Genomic Classifier - https://t.co/6VCW4sx9ni

🔗 Prosigna® Breast Risk of Recurrence Test - https://t.co/vGSwkG60Z9

🔗 For more event information: https://t.co/Q0oG9U9IOm
#MolecularTesting #Pathology #PrecisionOncology #MolecularPathology